Prognostic value of soluble biomarkers of haemodynamic stress, inflammation and fibrosis in hfpef: a retrospective cohort study

Filatova AYu, Sobolevskaya MS, Potekhina AV, et al. . Prognostic value of soluble biomarkers of haemodynamic stress, inflammation and fibrosis in hfpef: a retrospective cohort study. Russian Cardiology Bulletin. 2024;19(2):47‑54. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20241902147

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate prognostic role of inflammatory and fibrosis biomarkers in patients with heart failure and preserved ejection fraction (HFpEF).

MATERIAL AND METHODS

A retrospective cohort study included 348 outpatients with HFpEF who underwent clinical and instrumental evaluation between 2013 and 2020. The follow-up period was at least 3 years (median 5.4 years). The diagnosis of HFpEF was based on symptoms and signs of heart failure (HF), LV ejection fraction ≥50% and increased LV filling pressure. The primary endpoint was all-cause mortality and hospitalization due to exacerbation of HF. At baseline, we estimated serum (NT-proBNP), biomarkers of inflammation (highly sensitive C-reactive protein [hsCRP]) and fibrosis (growth differentiation factor-15 [GDF-15] and soluble interleukin 1 receptor-like 1 [sST2]). Survival rates were estimated using the Kaplan-Meier multiplier estimation method.

RESULTS. P

Rimary complication occurred in 48% of patients. NT-proBNP (relative risk [RR] 1.44, 95% CI 1.05 to 1.96, p=0.002) and GDF-15 (RR 1.68, 95% CI 1.02 to 2.77, p=0.043) were significantly associated with poor prognosis. Significance of hsCRP was unclear (p=0.07). Prognostic significance of NT-proBNP was superior to routine echocardiographic parameters characterizing diastolic dysfunction/LV filling pressure: left atrial volume index, pulmonary artery systolic pressure (PASP), ratio of early diastolic filling velocity to early diastolic LV base elevation velocity (E/e’) and LV mass index. Prognostic significance of GDF-15 was superior to PASP, E/e’ ratio and LV mass index.

CONCLUSION

Prognostic significance of GDF-15 and high prognostic role of myocardial stress marker NT-proBNP were confirmed in a large national ambulatory cohort of patients with HFpEF. Both biomarkers were superior to many routine echocardiographic parameters.

Keywords:

HFpEF

NT-proBNP

GDF-15

chronic inflammation

myocardial fibrosis

diastolic dysfunction

echocardiography

Authors:

Filatova A.Yu.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0001-8911-1628

Sobolevskaya M.S.

Chazov National Medical Research Center for Cardiology

ORCID: 0009-0006-7641-5191

Potekhina A.V.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0001-9290-9884

Svirida O.N.

Chazov National Medical Research Center for Cardiology

ORCID: 0000-0003-1317-036X

Masenko V.P.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0003-3280-3521

Kuznetsova T.V.

Chazov National Medical Research Center for Cardiology

ORCID: 0000-0001-5403-3885

Sharf T.V.

Chazov National Medical Research Center for Cardiology

ORCID: 0000-0003-1993-9264

Ageev F.T.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0003-3285-6148

Ovchinnikov A.G.

Chazov National Medical Research Center of Cardiology;
Evdokimov Moscow State University of Medicine and Dentistry

ORCID: 0000-0003-3285-6148

Received:

25.03.2024

Accepted:

26.03.2024

Close metadata

References:

Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, Aragam J, Benjamin EJ, Larson MG. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging. 2018;11(1):1-11. https://doi.org/10.1016/j.jcmg.2017.08.007
Ovchinnikov AG, Arefieva TI, Potekhina AV, Filatova AY, Ageev FT, Boytsov SA. The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction. Acta Naturae. 2020;12(2):40-51. https://doi.org/10.32607/actanaturae.10990
Eltelbany M, Shah P, deFilippi C. Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping. Curr Heart Fail Rep. 2022;19(6):412-424. https://doi.org/10.1007/s11897-022-00578-7
Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, Bozkurt B, Butler J, Chioncel O, Cleland JGF, Christodorescu R, Del Prato S, Gustafsson F, Lam CSP, Moura B, Pop-Busui R, Seferovic P, Volterrani M, Vaduganathan M, Metra M, Rosano G. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891-1898. https://doi.org/10.1002/ejhf.3036
Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872-881. https://doi.org/10.1002/ejhf.2206
Lakhani I, Wong MV, Hung JKF, Gong M, Waleed KB, Xia Y, Lee S, Roever L, Liu T, Tse G, Leung KSK, Li KHC. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2021;26(5):1141-1150. https://doi.org/10.1007/s10741-020-09927-x
Ramirez MF, Lau ES, Parekh JK, Pan AS, Owunna N, Wang D, McNeill JN, Malhotra R, Nayor M, Lewis GD, Ho JE. Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF. Circ Heart Fail. 2023;16(11):e010618. https://doi.org/10.1161/CIRCHEARTFAILURE.123.010618
Gui XY, Rabkin SW. C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis. Curr Heart Fail Rep. 2023;20(1):1-11. https://doi.org/10.1007/s11897-022-00584-9
Taqueti VR, Shah AM, Everett BM, Pradhan AD, Piazza G, Bibbo C, Hainer J, Morgan V, Carolina do A H de Souza A, Skali H, Blankstein R, Dorbala S, Goldhaber SZ, Le May MR, Chow BJW, deKemp RA, Hage FG, Beanlands RS, Libby P, Glynn RJ, Solomon SD, Ridker PM, Di Carli MF. Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial. JACC Basic Transl Sci. 2022;8(2):141-151. https://doi.org/10.1016/j.jacbts.2022.08.009
Lotierzo M, Dupuy AM, Kalmanovich E, Roubille F, Cristol JP. sST2 as a value-added biomarker in heart failure. Clin Chim Acta. 2020;501:120-130. https://doi.org/10.1016/j.cca.2019.10.029
Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, Kanaka-Gantenbein C, Tentolouris N, Papassotiriou I. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Crit Rev Clin Lab Sci. 2020;57(2):114-125. https://doi.org/10.1080/10408363.2019.1678565
Takvorian KS, Wang D, Courchesne P, Vasan RS, Benjamin EJ, Cheng S, Larson MG, Levy D, Ho JE. The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. Circ Heart Fail. 2023;16(1):e009446. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009446
Rabkin SW, Tang JK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with reduced ejection fraction: a systematic review. Heart Fail Rev. 2021;26(4):799-812. https://doi.org/10.1007/s10741-020-09913-3
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314. https://doi.org/10.1016/j.echo.2016.01.011
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol Med. 2020;12(10):e10865. https://doi.org/10.15252/emmm.201910865
Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, Spires TE, Yarde M, Wang Z, Seiffert DA, Prenner S, Zamani P, Bhattacharya P, Kumar A, Margulies KB, Car BD, Gordon DA, Moore JH, Cappola TP. Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2020;75(11):1281-1295. https://doi.org/10.1016/j.jacc.2019.12.069
Morfino P, Aimo A, Castiglione V, Vergano G, Emdin M, Clerico A. Biomarkers of HFpEF: natriuretic peptides, high-sensitive troponins and beyond. J Cardiovasc Dev Dis. 2022;9(8):256. https://doi.org/10.3390/jcdd9080256
Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. 2020;109(3):331-338. https://doi.org/10.1007/s00392-019-01513-y
AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2017;6(2):e004382. https://doi.org/10.1161/JAHA.116.004382
Pacho C, Domingo M, Núñez R, Lupón J, Núñez J, Barallat J, Moliner P, de Antonio M, Santesmases J, Cediel G, Roura S, Pastor MC, Tor J, Bayes-Genis A. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatr. 2018;18(1):109. https://doi.org/10.1186/s12877-018-0807-2
Watson CJ, Gallagher J, Wilkinson M, Russell-Hallinan A, Tea I, James S, O’Reilly J, O’Connell E, Zhou S, Ledwidge M, McDonald K. Biomarker profiling for risk of future heart failure (HFpEF) development. J Transl Med. 2021;19(1):61. https://doi.org/10.1186/s12967-021-02735-3
Cohen AJ, Teramoto K, Claggett B, Buckley L Jr, Solomon S, Ballantyne C, Selvin E, Shah AM. Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. J Card Fail. 2021;27(12):1382-1392. https://doi.org/10.1016/j.cardfail.2021.07.006
Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, Swat SA, Sanchez C, Njoroge J, Tan RS, Fermer ML, Gan LM, Lund LH, Lam CSP, Shah SJ. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020;142(21):2029-2044. https://doi.org/10.1161/CIRCULATIONAHA.120.045810
Shaik SP, Karan HH, Singh A, Attuluri SK, Khan AAN, Zahid F, Patil D. HFpEF: New biomarkers and their diagnostic and prognostic value. Curr Probl Cardiol. 2024;49(1 Pt C):102155. https://doi.org/10.1016/j.cpcardiol.2023.102155